A novel CXCR4 antagonist for hematopoietic stem cell mobilization.

Article Details

Citation
Copy to clipboard

Fricker SP

A novel CXCR4 antagonist for hematopoietic stem cell mobilization.

Expert Opin Investig Drugs. 2008 Nov;17(11):1749-60. doi: 10.1517/13543784.17.11.1749 .

PubMed ID
18922110 [ View in PubMed
]
Abstract

BACKGROUND: Hematopoietic stem cell (HSC) transplantation is a treatment option for hematological malignancies. Current mobilization regimes frequently result in inadequate numbers of HSC for transplant therefore alternative methods of mobilization are required. OBJECTIVE: The chemokine receptor CXCR4 and ligand SDF-1 are integrally involved in HSC homing and mobilization. Disruption of the SDF-1/CXCR4 axis by the CXCR4 anatagonist, plerixafor, is shown to improve HSC mobilization. METHODS: The molecular and in vivo pharmacology of plerixafor and subsequent clinical development is reviewed. RESULTS/CONCLUSION: Preclinical studies demonstrate that plerixafor is a selective antagonist of CXCR4 and can rapidly mobilize HSC. Clinical trials demonstrated improved HSC mobilization when plerixafor was included in the mobilization regimen. These data suggest the potential for a significant role for plerixafor in hematological disease.

DrugBank Data that Cites this Article

Drugs